Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 404-410

  Brufsky, Adam M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

21 gene recurrence score; Breast cancer; Costeffectiveness; Gene expression profiling; Prognosis

Indexed keywords

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENETIC MARKERS; HUMANS; NITRILES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; VALIDATION STUDIES AS TOPIC;

EID: 84905107681     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000086     Document Type: Review

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2011. Available at: http://seer.cancer. gov/csr/1975-2009-pops09/. Accessed November 1, 2013.
3. Eiermann W, Rezai M, Kümmel S, et al. The 21-gene Recurrence Score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 2013; 24: 618-624.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Breast Cancer, v. 2.2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed November 1, 2013.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
6. Wood WC, Anderson M, Lyles RH, et al. Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg. 2002; 235: 859-862.
7. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: Current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001; 6: 375-392.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012; 379: 432-444.
9. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010; 11: 55-65.
10. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28: 1829-1834.
11. Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008; 13: 477-493.
12. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2012; 104: 1068-1079.
13. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101: 1446-1452.
14. Ross DT, Kim CY, Tang G, et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res. 2008; 14: 6602-6609.
15. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010; 12: R47.
16. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3039-3047.
17. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98: 1183-1192.
18. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosissignature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009; 116: 295-302.
19. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31: 2783-2790.
20. Gnant M, Dowsett M, Filipits M, et al. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: a combined analysis of 2485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. J Clin Oncol. 2013; 31(suppl 15): abstract 506.
21. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.
22. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006; 24: 3726-3734.
23. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8: R25.
24. Mamounas EP, Tang G, Paik S, et al. Prognostic impact of the 21-gene Recurrence Score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. J Clin Oncol. 2012; 30(suppl 27): Abstract 1.
25. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21- gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008; 26: 4063-4071.
26. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131-2139.
27. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005; 23: 3686-3696.
28. Mamounas EP, Tang G, Paik S, et al. Association between the 21- Gene Recurrence Score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): results from NSABP B-28. Cancer Res. 2012; 72(suppl 24): abstract S1-S10.
29. Sparano JA, O'Neill A, Gray RJ, et al. 10-year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN + and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene Recurrence Score (RS) with clinicopathologic features. J Clin Oncol. 2012; 30(Suppl 15): abstract 1021.
30. Gonzalez-Angulo AM, Barlow WE, Gralow J, et al. SWOG S1007: A phase III randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with Recurrence Score (RS) of 25 or less. J Clin Oncol. 2011; 29(Suppl 15): abstract TPS104.
31. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating Oncotype DX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2012; 34: 1-9.
32. Clinicaltrials.gov. Tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer. Clinicaltrials.gov identifier NCT01272037. Available at: http://clinicaltrials.gov/show/NCT01272037. Accessed November 1, 2013.
33. Rezai M, Eiermann W, Kümmel S, et al. Impact of the Recurrence Score on adjuvant decision-making in ER-positive early breast cancer-results of a large prospective multicentre decision impact study in node negative and node positive disease. Cancer Res. 2011; 71(suppl 24): abstract P2-12-26.
34. de Boer RH, Baker C, Speakman D, et al. Australian Decision Impact Study: the impact of Oncotype DX Recurrence Score (RS) on adjuvant treatment decisions in hormone receptor positive (HR +), node negative (N0) and node positive (N +) early stage breast cancer (ESBC) in the multidisciplinary clinic (MDC). Cancer Res. 2011; 71(suppl 24): abstract P4-09-18.
35. Oratz R, Kim B, Chao C, et al. Physician survey of the effect of the 21-gene Recurrence Score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract. 2011; 7: 94-99.
36. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode- negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005; 11: 313-324.
37. Lyman GH, Cosler LE, Kuderer NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007; 109: 1011-1018.
38. Vanderlaan BF, Broder MS, Chang EY, et al. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manag Care. 2011; 17: 455-464.
39. Hornberger J, Chien R, Krebs K, et al. US insurance program's experience with a multigene assay for early-stage breast cancer. J Oncol Pract. 2011; 7: e38s-e45s.
40. Hall PS, McCabe C, Stein RC, et al. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012; 104: 56-66.
41. Drukker CA, van Tinteren H, Schmidt MK, et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat. 2014; 143: 587-592.
42. Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014; 25: 339-345.